05th week of 2021 patent applcation highlights part 24 |
Patent application number | Title | Published |
20210032168 | CERAMIC MATERIAL, LAYER AND LAYER SYSTEM - A ceramic material which contains yttrium oxide as the stabilizer and at least one of the materials erbium oxide or ytterbium oxide provides a phase having sintering stability for a ceramic material for ceramic layers and a ceramic layer system which maintain the mechanical and thermal properties for a long time even when used at high temperatures. | 2021-02-04 |
20210032169 | AQUEOUS SUSPENSION CONTAINING METAL CARBIDE PARTICLES - The present invention relates to aqueous suspensions containing 30 to 95 wt.-% metal carbide particles and a dispersant, and to a process for coating substrates using said aqueous suspensions. The invention also relates to the coated substrates that can be produced by the process according to the invention and to the uses thereof. | 2021-02-04 |
20210032170 | ACCELERATOR POWDER AND QUICK-SETTING BINDER COMPOSITION - An accelerator powder for cement and also rapid-setting binder compositions which contain the accelerator powder and the use in mortar or concrete. The accelerator powder includes from 10 to 99.7% by weight of a water-insoluble mineral powder P and from 0.3 to 90% by weight of at least one compound V selected from the group consisting of alkali metal halides and alkaline earth metal halides, alkali metal nitrates and alkaline earth metal nitrates, alkali metal nitrites and alkaline earth metal nitrites, alkali metal thiocyanates and alkaline earth metal thiocyanates and hydroxyalkylamines or salts thereof, and mixtures thereof. | 2021-02-04 |
20210032171 | NITRIDE CERAMIC RESIN COMPOSITE BODY - A nitride-based ceramics resin composite body having thermal conductivity, electrical insulation, and adhesion to adherends equal to conventional products, and having improved heat resistance reliability during the reflow process, and a thermal conductive insulating adhesive sheet using the same are provided. A nitride-based ceramics resin composite body in which a thermosetting resin composition is impregnated in a porous nitride-based ceramics sintered body is provided. The thermosetting resin composition includes a specific epoxy resin and a bismaleimide triazine resin, and a water absorption of the thermosetting resin composition in a completely cured state measured in accordance with method A in JIS K7209 (2000) is 1% by mass or less. | 2021-02-04 |
20210032172 | METHOD TO PRODUCE A PROTECTIVE SURFACE LAYER HAVING A PREDETERMINED TOPOGRAPHY ON A CERAMIC MATRIX COMPOSITE - A method to produce a protective surface layer having a predetermined topography on a ceramic matrix composite is described. The method includes applying a slurry layer to a surface of a fiber preform, and drying the slurry layer to form a particulate layer. A surface of the particulate layer is machined to improve surface smoothness and to form a machined surface. A ceramic tape is attached to the machined surface, and a tool comprising one or more features to be imprinted is placed on the ceramic tape, thereby forming a compression assembly. Heat and pressure are applied to the compression assembly to consolidate and bond the ceramic tape to the machined surface, while the one or more features of the tool are imprinted. Thus, a protective surface layer having a predetermined topography is formed. | 2021-02-04 |
20210032173 | POLYPHOSPHORIC ACID CALCIUM MAGNESIUM FERTILIZER, POLYPHOSPHORIC ACID CALCIUM MAGNESIUM FERTILIZER PREPARED BY USING PHOSPHORIC ACID AND PHOSPHORUS TAILINGS AS RAW MATERIALS AND PREPARATION METHOD THEREFOR - The present invention relates to a polyphosphoric acid calcium magnesium fertilizer prepared by using phosphoric acid and phosphorus tailings as raw materials and a preparation method therefor. The polyphosphoric acid calcium magnesium fertilizer is prepared by using phosphorus tailings and phosphoric acid as raw materials. Based on P | 2021-02-04 |
20210032174 | SEED, SOIL, AND PLANT TREATMENT COMPOSITIONS - Various seed, soil, and plant treatment compositions, methods of applying such compositions, and the like are described herein. The treatment compositions can comprise one or more zinc compounds, one or more iron compounds, and/or one or more molybdenum compounds. Applications of the treatment compositions can include being placed in-furrow, side-dressed in fields, used as foliar treatments, broadcast in soil, tilled in soil, or otherwise applied to seeds, soils, or plants. | 2021-02-04 |
20210032175 | Novel Soil Amendment with Reduced Metal Content for Reducing Metal Uptake by Growing Plants, and Processes for Making and Using Same - is grown on purified chitin obtained by fermentation of micronized shrimp or crab shell material and purification using alkaline media. The chitin is biodegraded by the | 2021-02-04 |
20210032176 | USE OF N-FUNCTIONALIZED ALKOXY PYRAZOLE COMPOUNDS AS NITRIFICATION INHIBITORS - The present invention relates to the use of novel nitrification inhibitors of formula (I), which are N-functionalized alkoxy pyrazole compounds. Moreover, the invention relates to the use of compounds of formula (I) as nitrification inhibitors, i.e. for reducing nitrification, as well as agrochemical mixtures and compositions comprising the nitrification inhibitors of formula (I). | 2021-02-04 |
20210032177 | AGRICULTURAL COMPOSITIONS - This document provides compositions comprising (or consisting essentially of or consisting of) one or more water-soluble oils selected from the group consisting of ethoxylated macadamia oil, ethoxylated olive oil, ethoxylated avocado oil, ethoxylated meadowfoam oil, ethoxylated almond oil, ethoxylated corn oil, ethoxylated soybean oil, ethoxylated jojoba oil, ethoxylated seabuckthorn oil (e.g., fruit, berry, or seed oil), ethoxylated emu oil, ethoxylated mink oil, PEG Glyceryl Dimyristate, PEG Glyceryl Dioleate, PEG Glyceryl Distearate, and PEG Glyceryl Palmitate; and one or more agricultural chemical or biological agents. Methods for making and using the compositions also are provided. | 2021-02-04 |
20210032178 | ENCAPSULATION OF ACTIVE SUBSTANCES AND/OR MICRO-ORGANISMS IN A LAMELLAR MATERIAL - The present invention relates to a method for encapsulating a compound selected from the group consisting of at least one active substance, at least one microorganism and mixtures thereof in an organic-inorganic hybrid material of 2:1 lamellar structure, said material having the following general formula I: Na | 2021-02-04 |
20210032179 | COMPOSITE BASED ON A LAMELLAR MATERIAL AND A POROUS MATERIAL COMPRISING AN ACTIVE SUBSTANCE AND/OR A MICROORGANISM - The present invention concerns a process for preparing a composite of porous material/compound/hybrid organic-inorganic material having a 2:1 lamellar structure, said hybrid material having the following general formula I: | 2021-02-04 |
20210032180 | IGNITION BOOSTER COMPOSITIONS AND METHODS OF MAKING THE SAME - An igniter composition has (i) a source of copper selected from basic copper nitrate, copper oxide, copper hydroxide, and/or copper complex of guanylurea nitrate, (ii) one or more oxidizers, (iii) a binder selected from guanidine nitrate and/or guanylurea nitrate, and (iv) an inorganic fuel comprising an elemental metal or metal hydride selected from the group consisting of: titanium, silicon, aluminum, magnesium, iron, and combinations thereof. The igniter composition may be substantially free of boron or contain minimal amounts of boron. A minimum flame temperature at combustion (T | 2021-02-04 |
20210032181 | DIFLUOROMETHOXYLATION AND TRIFLUOROMETHOXYLATION COMPOSITIONS AND METHODS FOR SYNTHESIZING SAME - The present invention provides a compound having the structure: | 2021-02-04 |
20210032182 | Xylene Production Processes and Systems - A process and related system for producing para-xylene (PX). In an embodiment, the process includes (a) separating a feed stream comprising C | 2021-02-04 |
20210032183 | GAS-TO-GAS REACTOR AND METHOD OF USING - A device and a process to propagate molecular growth of hydrocarbons, either straight or branched chain structures, that naturally occur in the gas phase of a first gas to gas phase molecules of a second gas having higher molecular chain lengths than the hydrocarbons of the first gas. According to one embodiment, the device includes a grounded reactor vessel having a gas inlet, a product outlet, and an electrode within the vessel; a power supply coupled to the electrode for creating an electrostatic field within the vessel for converting the first gas to a second gas. | 2021-02-04 |
20210032184 | RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOF - Described herein are labeling agents, specifically [ | 2021-02-04 |
20210032185 | METHOD FOR THE PREPARATION OF C3-C12-ALCOHOLS BY CATALYTIC HYDROGENATION OF THE CORRESPONDING ALDEHYDES - The present invention relates to a process for preparing C | 2021-02-04 |
20210032186 | IRON (III) CITRATE, SUBSTANTIALLY FREE OF BETA-IRON HYDROXIDE OXIDE - This invention provides a method for producing high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, high-purity iron(III) citrate substantially free of beta-iron hydroxide oxide, and medical uses thereof. | 2021-02-04 |
20210032187 | METHOD OF PRODUCING A 2-((METH)ALLYLOXYMETHYL)ACRYLIC ACID DERIVATIVE, AND 2-((METH)ALLYLOXYMETHYL)ACRYLIC ACID ALKALI METAL SALT POWDER - Provided is a method of producing various 2-((meth)allyloxymethyl)acrylic acid derivatives in high yields with no need to load a raw material in a large excess for improving a reaction conversion ratio, and without use of a catalyst having high toxicity or a strong acid catalyst. Also provided are powder compounds that may be utilized as raw materials for synthesizing various chemical products. A method of producing a 2-((meth)allyloxymethyl)acrylic acid derivative includes causing the powder of a salt of a 2-((meth)allyloxymethyl)acrylic acid anion and an alkali metal cation (component A), and a halide (component B) to react with each other to produce a 2-((meth)allyloxymethyl)acrylic acid derivative. The 2-((meth)allyloxymethyl)acrylic acid alkali metal salt powder is the powder of a salt of a 2-((meth)allyloxymethyl)acrylic acid anion and an alkali metal cation, and has a bulk density of 0.50 g/mL or more, or a water content of 0.05 wt % or less. | 2021-02-04 |
20210032188 | ADVANCED ADSORPTION PROCESSES FOR SEPARATION OF BIO-DERIVED PRODUCTS - Disclosed herein are methods for the recovery of target bio-based products using a sorption-based technology with a mixed elution solvent optimized for minimized downstream distillation energy input. | 2021-02-04 |
20210032189 | HYDROGENATION OF AROMATIC COMPOUNDS - Process for hydrogenating aromatic compounds over a solid catalyst in the presence of a hydrogen-containing gas comprising a first reactor operated in loop mode, a second reactor operated in straight pass, at least part of the output of the first reactor is supplied to the second reactor, characterized in that the first reactor is configured as a trickle bed reactor and is operated in trickle bed mode and the second reactor is operated such that the catalyst present therein is partially flooded. | 2021-02-04 |
20210032190 | CYCLOPROPYL ETHYLENE COMPOUND AND ARTHROPOD PEST CONTROL COMPOSITION CONTAINING SAME - The present invention provides a compound that have excellent harmful arthropod controlling effects, the compounds being represented by formula (I) [wherein R | 2021-02-04 |
20210032191 | PRODUCTION METHOD FOR 1,4-CYCLOHEXANEDICARBOXYLIC ACID DERIVATIVE, 1,4-DICYANOCYCLOHEXANE AND 1,4-BIS(AMINOMETHYL)CYCLOHEXANE - A production method for producing a 1,4-cyclohexanedicarboxylic acid derivative, involves subjecting an aqueous ammonia solution of 1,4-cyclohexanedicarboxylic acid to heat concentration, thereby precipitating a 1,4-cyclohexanedicarboxylic acid derivative as a crystal. | 2021-02-04 |
20210032192 | CATIONIC LIPIDS AND TRANSFECTION METHODS - The present invention relates in part to novel cationic lipids and their use, e.g., in delivering nucleic acids to cells. | 2021-02-04 |
20210032193 | FOXM1 INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAME - Provided are compounds, or pharmaceutically acceptable salts thereof, which are useful for inhibiting FOXM1, inhibiting cancer growth, and/or treating cancer. In particular, these compounds and their corresponding quaternary ammonium salts may be used to treat various forms of breast cancer. | 2021-02-04 |
20210032194 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES - The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases. | 2021-02-04 |
20210032195 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF - Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity. | 2021-02-04 |
20210032196 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS - The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels. | 2021-02-04 |
20210032197 | METHOD FOR PRODUCING NITRILE - The present invention provides a method of producing a nitrile from a primary amide, characterized in that the primary amide is subjected to a dehydration reaction in a supercritical fluid in the presence of an acid catalyst. The present invention achieves the object of reducing the corrosion of a reactor and the thermal decomposition of raw materials, as well as provides the effect of improving the reaction rate and nitrile selectivity. | 2021-02-04 |
20210032198 | COMPOUNDS FOR USE AS INHIBITORS OF ALTERNATIVE OXIDASE OR CYTOCHROME BC1 COMPLEX - The invention provides compounds for use in inhibiting a microbial alternative oxidase (AOX) and/or cytochrome bc | 2021-02-04 |
20210032199 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF - Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain. | 2021-02-04 |
20210032200 | RADICAL INITIATORS AND CHAIN EXTENDERS FOR CONVERTING METHANE GAS INTO METHANE-SULFONIC ACID - Improved initiators, solvents, and SO3 mixtures are disclosed herein, which can increase the yields and efficiency of a chemical manufacturing process which uses a radical chain reaction to convert methane (CH4), which is a gas under any normal conditions, into methane-sulfonic acid (MSA), a liquid. MSA is useful and valuable in its own right, and it also can be processed to create desulfured fuels and other valuable chemicals. A preferred initiator combination has been identified, comprising at least two different sulfate peroxide compounds. One type or class of initiator can be called a “primary” (or major, main, principle, dominant, or similar terms) initiator, and the other type or class of initiator can be can be regarded as an “extender” (or secondary, supplemental, enhancing, tuning, tweaking, or similar terms) initiator. “Primary” initiator(s) include (unmethylated) Marshall's acid, mono-methyl-Marshall's acid, and di-methyl-Marshall's acid, while a secondary/extender initiator comprises methyl-Caro's acid, which can oxidize sulfur DI-oxide (an unwanted chain terminator) into sulfur TRI-oxide (an essential reagent). Various other enhancements to the MSA manufacturing process also are described. | 2021-02-04 |
20210032201 | PERFLUORO DIACYL PEROXIDE, SOLUTION, POLYMERIZATION INITIATOR, POLYMER PREPARATION METHOD, AND PERFLUORO ACYL CHLORIDE - A perfluorodiacyl peroxide represented by the following formula (1): | 2021-02-04 |
20210032202 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF - A compound of Formula (1) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: | 2021-02-04 |
20210032203 | SALTS OF AN LSD1 INHIBITOR - The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer. | 2021-02-04 |
20210032204 | NOVEL SALT FORMS OF URAT-1 INHIBITORS - Provided herein are compounds, salts, crystalline forms, and pharmaceutical compositions that are related to thiobutyrate compounds, such as Compound (1) and its salts (such as sodium, potassium, and calcium salt), as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, crystalline forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as gout and hyperuricemia. | 2021-02-04 |
20210032205 | HETEROARYL SULFONAMIDE COMPOUND AND FORMULATION FOR CONTROLLING HARMFUL ORGANISMS - The present invention relates to a compound represented by formula (I) or a salt thereof which has excellent insecticidal, acaricidal and/or nematicidal activity, exhibits excellent safety, and can be advantageously synthesized industrially, and also relates to a formulation for controlling harmful organisms which contains the same. | 2021-02-04 |
20210032206 | 2-Alkoxy-6-[18F]fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues | 2021-02-04 |
20210032207 | QUINOLONE COMPOUND - The present invention provides a compound represented by the formula (T) | 2021-02-04 |
20210032208 | COMPOUND, PHOTORESIST COMPOSITION COMPRISING SAME, PHOTORESIST PATTERN COMPRISING SAME, AND METHOD FOR MANUFACTURING PHOTORESIST PATTERN - A compound represented by Chemical Formula 1, a photoresist composition comprising the same, a photoresist pattern comprising the same, and a method for preparing a photoresist pattern | 2021-02-04 |
20210032209 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are kinase inhibitors, their polymorphs, pharmaceutical compositions and methods of treatment of cancer are described herein. | 2021-02-04 |
20210032210 | CO-CRYSTALS - The present document is directed to co-crystals of resveratrol and/or curcumin with piperazine and their use in medicine and/or as food and feed supplements. | 2021-02-04 |
20210032211 | PROCESSES FOR THE SYNTHESIS OF SULFENTRAZONE - Disclosed are processes for the synthesis of sulfentrazone, which provide a high conversion of sulfentrazone amine and high yield of the final sulfentrazone product. | 2021-02-04 |
20210032212 | METHOD FOR THE PREPARATION OF A 2,4,5-TRISUBSTITUTED 1,2,4-TRIAZOLONE - The present invention provides methods for the preparation of Compound (I): Compound (I), the use of intermediates for the preparation of said compound and its crystalline form A. | 2021-02-04 |
20210032213 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS - Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I). | 2021-02-04 |
20210032214 | COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 - The present disclosure relates to novel compounds, methods, and compositions capable of binding to PCSK9, thereby modulating PCSK9 proprotein convertase enzyme activity. The compounds of the disclosure include compounds Formula (I). | 2021-02-04 |
20210032215 | CONVERSION OF 1,2,5,6-HEXANETETROL (HTO) TO TETRAHYDROFURAN dicarboxylic acid (THFDCA) - Disclosed herein are methods for synthesizing useful intermediates and/or products from 1,2,5,6-hexanetetrol (HTO), which itself can be derived from a sugar. In an aspect, a process is provided for production of THFDCA from 1,2,5,6-hexanetetrol (HTO). The process comprises the steps of (a) ring closing to form a ring compound and (b) oxidizing using a catalyst comprising platinum and bismuth to form an acid mixture. Step (a) may be performed before or after step (b). | 2021-02-04 |
20210032216 | A PROCESS FOR THE CONVERSION OF A SOLID LIGNOCELLULOSIC MATERIAL - A process for the conversion of solid lignocellulosic material containing hemicellulose, cellulose and lignin, includes (a) hydrolyzing, at a temperature equal to or less than 40° C. at least part of the hemicellulose and at least part of the cellulose of the solid lignocellulosic material with an aqueous hydrochloric acid solution, containing in the range from equal to or more than 40.0 wt. % to equal to or less than 51.0 wt. % hydrochloric acid, based on the combined weight amount of water and hydrochloric acid in the aqueous hydrochloric acid solution; yielding a hydrochloric acid-containing, aqueous hydrolysate solution; (b) separating the hydrochloric acid-containing, aqueous hydrolysate solution from the lignin; and (c) heating at least part of the hydrochloric acid-containing, aqueous hydrolysate solution to a temperature equal to or more than 60° C., yielding a product solution containing 5-(chloromethyl)furfural, and extracting the 5-(chloromethyl)furfural from the product solution into an extraction solvent. | 2021-02-04 |
20210032217 | PROCESS FOR THE CONVERSION OF A SOLID LIGNOCELLULOSIC MATERIAL - A process includes the following steps: a) converting a solid material containing hemicellulose, cellulose and lignin, by: (i) hydrolyzing at least part of the hemicellulose of the solid material with a first aqueous hydrochloric acid solution, yielding a remaining solid material and a hydrochloric acid- containing, aqueous, first hydrolysate product solution; (ii) hydrolyzing at least part of the cellulose of the remaining solid material with a second aqueous hydrochloric acid solution, yielding a residue and a hydrochloric acid-containing, aqueous, second hydrolysate product solution; (b) forwarding to step (c) a, hydrochloric acid-containing, aqueous intermediate product solution comprising: a part of or the whole of the hydrochloric acid-containing, aqueous first and/or second hydrolysate product solution of step (a); and (c) heating at least part of the hydrochloric acid-containing, aqueous intermediate product solution to yield a product solution containing 5-(chloromethyl)furfural, and extracting the 5-(chloromethyl)furfural from the product solution into an extraction solvent. | 2021-02-04 |
20210032218 | SUCCINATE FORMS AND COMPOSITIONS OF BRUTON'S TYROSINE KINASE INHIBITORS - The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. | 2021-02-04 |
20210032219 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF - A quaternary lactam compound of formula (I). The compound is used in the manufacture of a medicament for the treatment and/or prevention of thrombotic or thromboembolic disorders. | 2021-02-04 |
20210032220 | HETEROCYCLIC COMPOUNDS COMPRISING PYRIDINE USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES - Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R | 2021-02-04 |
20210032221 | 1,2,3-TRIAZOLE INHIBITORS OF P97 AAA ATPASE ACTIVITY - The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by modulation of p97. | 2021-02-04 |
20210032222 | FIVE-MEMBERED RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOF - The invention belongs to the technical field of agricultural chemicals, and in particular relates to a five-membered ring-substituted pyridazinol compound and a derivatives thereof, preparation method, herbicidal composition and application thereof. The compound is as shown in Formula I: | 2021-02-04 |
20210032223 | CRYSTAL FORM OF SMALL MOLECULE IMMUNE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Provided in the present invention are a crystal form of a small molecule immune compound, a preparation method therefor and a pharmaceutical composition containing the same; the compound is (3Z,6Z)-3-[((E)-3-(5-tert-butyl)-1H-imidazolyl-4-yl)methylene]-6-((E)-3-(3-fluorophenyl)-2-propenylene)piperazine-2,5-dione; the crystal form thereof has stable morphology, good chemical stability, high temperature resistance, and is used for treating hyperproliferative diseases. The structural formula of the compound is as shown in formula (I). | 2021-02-04 |
20210032224 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF - A heteroaryl[4,3-c]pyrimidin-5-amine derivative, a preparation method therefor, and medical uses thereof are provided. Specifically, a heteroaryl[4,3-c]pyrimidin-5-amine derivative of formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and uses thereof as therapeutic agents are provided. In particular, the provided compounds can be used as Ata receptor antagonists and for treatment of conditions or symptoms that are ameliorated by inhibiting the Ata receptor. The various substituent groups in the formula (I) have the meanings as described in the specification. | 2021-02-04 |
20210032225 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are novel organic molecules containing fused indole and benzimidazole moieties, or their boron containing analogs. Also provided are OLEDs and related consumer products that utilize these compounds containing the fused indole and benzimidazole moieties. | 2021-02-04 |
20210032226 | A PROCESS FOR THE PREPARATION OF LIFITEGRAST - The present invention provides dibenzylamine salt of Lifitegrast (XV), and diphenylamine salt of Lifitegrast (XVI) and the use of the above salts in the purification process of Lifitegrast (I). The present invention relates to a process for the preparation of Lifitegrast (I). | 2021-02-04 |
20210032227 | ARYLNAPHTHALENE COMPOUNDS AS VACUOLAR-ATPASE INHIBITORS AND THE USE THEREOF - Ebola virus and Marburg virus are filoviruses and are responsible for outbreaks that cause up to 90% fatality, including the recent outbreak in West Africa that has resulted in over 11,000 deaths. The present disclosure generally relates to novel arylnaphthalene compounds as a vacuolar-ATPase inhibitor that are useful for the treatment of various viral infections, including those infections caused by filoviruses. Pharmaceutical composition matters and methods of use are within the scope of this invention. | 2021-02-04 |
20210032228 | ELECTRO-OPTIC POLYMER - The present invention provides an electro-optic polymer (EO polymer) comprising an electro-optic molecule (EO molecule) and a base polymer. The EO polymer of the present invention has good performance over the entire optical communication wavelength range and therefore can preferably be used for the production of optical modulators, optical switches, optical transceivers, optical phased arrays, LiDAR (light detection and ranging) devices, electric field sensors, terahertz wave generators and detectors, etc. | 2021-02-04 |
20210032229 | PYRIDINE RING-SUBSTITUTED PYRIDAZINOL COMPOUNDS AND DERIVATIVES, PREPARATION METHODS, HERBICIDAL COMPOSITIONS AND APPLICATIONS THEREOF - The invention belongs to the technical field of agricultural chemicals, and in particular relates to a pyridine ring-substituted pyridazinol compound and a derivatives thereof, preparation method, herbicidal composition and application thereof. The compound is as shown in Formula I: | 2021-02-04 |
20210032230 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof - Alkoxybenzeno five- or six-member heterocyclic amines compounds, their pharmaceutically acceptable salts, and pharmaceutical compositions are used as the active ingredients, and their application in drugs which can prevent and cure diseases caused by abnormal increasing of SM. These diseases caused by abnormal increasing of SM include atherosclerosis, type II diabetes, fatty liver, obesity, metabolic syndromes, enteritis and other inflammatory diseases. | 2021-02-04 |
20210032231 | Compounds and Their Use as PDE4 Activators - The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP). | 2021-02-04 |
20210032232 | CRYSTALLINE SALTS OF PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR - Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof. | 2021-02-04 |
20210032233 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer - The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders. | 2021-02-04 |
20210032234 | PYRAZOL-3-ONES THAT ACTIVATE PRO-APOPTOTIC BAX - This application features pyrazol-3-one compounds that activate pro-apoptotic BAX. Also featured are methods of using such compounds, e.g., for the treatment or prevention of diseases, disorders, and conditions associated with deregulated apoptosis of cells (e.g., insufficient apoptosis of diseased or damaged cells or essentially the absence of apoptosis of diseased or damaged cells). | 2021-02-04 |
20210032235 | CRYSTALLINE FORMS OF DASATINIB - The present disclosure relates to a dasatinib co-crystal form comprising dasatinib and a second compound, also referred to as a co-crystal former, wherein the second compound is selected from butyl paraben, propyl paraben and ethyl vanillin. The present disclosure is also related to an ethyl formate solvate form of dasatinib. The present disclosure is also related to processes for the preparation of the dasatinib co-crystal and solvate forms of dasatinib. Further, the present disclosure also relates to pharmaceutical compositions comprising the dasatinib co-crystal and solvate forms of dasatinib and methods for treating disease using the dasatinib co-crystal and solvate forms of dasatinib. | 2021-02-04 |
20210032236 | NOVEL GLUTAMINASE INHIBITORS - The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders involving glutamine. | 2021-02-04 |
20210032237 | NOVEL CATHODE BUFFER LAYER MATERIAL AND ORGANIC PHOTOELECTRIC DEVICE INCLUDING SAME - The present invention relates to a novel cathode buffer layer material and an organic photoelectric device including the same. When the novel compound of the present invention is applied to a cathode buffer layer of an organic photoelectric device, for example, an organic solar cell or an organic photodiode, there is an effect in which the surface characteristics of an electron transport layer are improved through the high dipole moment of the novel compound to thereby facilitate electron extraction from a photoactive layer to a cathode electrode and to reduce series resistance and leakage current, and accordingly, the performance of an organic optoelectronic device (organic solar cell, organic photodiode, etc.) to be manufactured can be remarkably improved, which is industrially advantageous. | 2021-02-04 |
20210032238 | ANTI-INFLUENZA VIRUS PYRIMIDINE DERIVATIVE - The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. | 2021-02-04 |
20210032239 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF - The invention provides novel chemical compounds useful for treating one or more of autoimmune diseases, cancer, cardiovascular diseases, inflammatory diseases and diabetes, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof. | 2021-02-04 |
20210032240 | CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO - The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPK1) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as | 2021-02-04 |
20210032241 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF - Disclosed are an aromatic heterocyclic compound, an intermediate thereof, a preparation method therefor, and a pharmaceutical composition and use thereof. The aromatic heterocyclic compound of the present invention is a new ALK5 inhibitor, and is used for treating and/or preventing various ALK5-mediated diseases. | 2021-02-04 |
20210032242 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF - Provided in the present application are an aromatic heterocyclic substituted olefin compound, a preparation method for same, a pharmaceutical composition of same, and applications thereof. The aromatic heterocyclic substituted olefin compound of the present invention is a novel ALK5 inhibitor and is for use in treating and/or preventing various ALK5-mediated diseases. | 2021-02-04 |
20210032243 | CONTINUOUS PROCESS FOR THE PREPARATION OF TRAZODONE - The present invention relates to an improved process for the preparation of trazodone. In particular, the present invention relates to a continuous process for the preparation of trazodone. More in particular, the present invention relates to a new method for the preparation of trazodone, said method comprising at least one step consisting of a continuous process performed in a flow reactor. | 2021-02-04 |
20210032244 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS - The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer. | 2021-02-04 |
20210032245 | SPIROCYCLIC COMPOUNDS - The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation. | 2021-02-04 |
20210032246 | METHODS FOR PREPARING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS - The present disclosure relates to novel, scalable methods of making substituted tricyclic compounds that are useful to treat and/or prevent HBV and/or HBV-HDV infection and related conditions in a subject. | 2021-02-04 |
20210032247 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-(6Br,10aS)-3-METHYL-2, 3, 6b, 9, 10, 10a-HEXAHYDRO-1H, 7H-PYRIDO[3', 4', 5] PYROLO[1,2,3-de] QUINOXALIN-8YL)- 1- (4-FLUOROPHENYL)-BUTANE-1-ONE AND METHODS OF TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM - The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one, and methods of use in the treatment of diseases involving 5-HT | 2021-02-04 |
20210032248 | DUAL SELECTIVE PI3 DELTA AND GAMMA KINASE INHIBITORS - The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them. | 2021-02-04 |
20210032249 | AMIDE DERIVATIVE INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF - An amide derivative inhibitor and a preparation method and an application thereof are provided. Specifically, a compound shown in general formula (I), a preparation method for same, a pharmaceutical composition containing the compound, and an application of same as an ASK inhibitor are provided. The disclosed compounds can be used for the treatment of neurodegenerative diseases, cardiovascular diseases, inflammation, autoimmune and metabolic diseases. Each of the substituents in the general formula (I) is as defined in the description. | 2021-02-04 |
20210032250 | GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS - The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: | 2021-02-04 |
20210032251 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 - The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer. | 2021-02-04 |
20210032252 | PRC2 Inhibitors - The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. | 2021-02-04 |
20210032253 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE-2-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF - Disclosed are a pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative and the use of same as a therapeutic agent, in particular the use thereof as an A | 2021-02-04 |
20210032254 | PROCESS FOR PREPARING SOLUBLE GUANYLATE CYCLASE STIMULATORS - The invention relates to novel methods for preparing 3-substituted 1,2,4-triazole compounds as sGC stimulators and their synthetic precursors. | 2021-02-04 |
20210032255 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE - The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. | 2021-02-04 |
20210032256 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives - The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain. | 2021-02-04 |
20210032257 | (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-- CARBOXYLATE FOR INHIBITING CDK7 - The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: | 2021-02-04 |
20210032258 | CRYSTALLINE FORMS OF A BRUTONS TYROSINE KINASE INHIBITOR - Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2021-02-04 |
20210032259 | CYCLIC ETHER DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXYAMIDE - The invention relates to Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (I) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention. | 2021-02-04 |
20210032260 | Beta-lactamase inhibitor and use thereof - Provided are a β-lactamase inhibitor of formula (I), or an ester, a stereoisomer or a pharmaceutically acceptable salt thereof, and a method of preparing the same. Further provided is a pharmaceutical composition comprising the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for treating diseases caused by bacterial infection, which comprises administering the β-lactamase inhibitor of formula (I), or the ester, the stereoisomer or the pharmaceutically acceptable salt thereof to a patient or a subject in need. | 2021-02-04 |
20210032261 | ANTIMICROBIAL AND ANTICANCER CATIONIC PHTHALOCYANINE COMPOUNDS - Substituted phthalocyanines for the generation of singlet oxygen in which one or more of the substituents bear a cationically charged N-alkylated pyridine. | 2021-02-04 |
20210032262 | PROCESS FOR PREPARING SUBSTITUTED CYCLOHEXANE AMINO ACID ESTERS AND SPIROKETAL-SUBSTITUTED CYCLIC KETO-ENOLS - The present invention relates to a novel process for preparing substituted cyclohexane amino acid esters and spiroketal-substituted cyclic keto-enols, and to novel intermediates or starting compounds that are passed through or used in the process according to the invention. | 2021-02-04 |
20210032263 | Compounds for the Treatment of Kinase-Dependent Disorders - Disclosed herein are compounds of Formula I′. Compounds of Formula I′ inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 2021-02-04 |
20210032264 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION - Compounds of formula (I): wherein, R | 2021-02-04 |
20210032265 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY - Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein. | 2021-02-04 |
20210032266 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating A Patient - Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity are provided in the present invention. The compositions of the present invention possess dual activity in a single agent of potent vascular endothelial growth factor receptor inhibitory activity as well as antitubulin activity. Water soluble salts of these compositions are also described. Methods of treating a patient having cancer, macular degeneration, and arthritis with the compositions and salts thereof of the present invention are disclosed. | 2021-02-04 |
20210032267 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS - The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders. | 2021-02-04 |